Spiriva Generic Must Deliver To Maintain Exit Margin Estimates At Lupin
Q1 Results Reflect Return To Form After Muted Performance
The performance of its recently-launched Spiriva generic will be crucial for Lupin’s future performance, as it forecasts year-end exit margins in the high teens.
You may also be interested in...
Self-labelled ‘disruptor’ Mark Cuban has brought on board yet another high-demand prescription drug, following a recent deal for biosimilar Humira.
Indian respiratory player Lupin has begun shipping its US generic version of Boehringer Ingelheim’s Spiriva HandiHaler, amid plans both to capture share from the originator’s follow-on soft mist inhalation brand and continue development of its own Respimat rival product.
Lupin has gained a long-awaited FDA approval for its US generic version of Spiriva. The product is seen as a major element of Lupin’s respiratory franchise and a key contributor to the Indian firm’s fortunes this year.